Non-alcoholic fatty liver disease (NAFLD) and its progressive form Non-alcoholic steatohepatitis (NASH) are reaching an epidemic growth. If uncontrolled, NASH can progress to liver adenocarcinoma that necessitates liver transplant. To date, there is no FDA-approved drug against NAFLD/NASH, owing largely to our limited understanding of its underlying mechanisms. Moreover, NASH is linked strongly to atherosclerosis and cardiovascular abnormalities of the metabolic syndrome. The Najjar laboratory has focused on delineating a unifying mechanism of these cardiometabolic abnormalities with an overarching goal to gain a thorough insight on their pathogenesis and develop more effective therapies.